이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

genedrive 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

James Cheek

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.9yrs

최근 관리 업데이트

Recent updates

CEO

James Cheek (57 yo)

less than a year

테뉴어

Mr. James Cheek is Chief Executive Officer & Director of genedrive plc from September 11, 2023. He has extensive commercial and operational experience. He has experience working at Cepheid, Beckman Coulter...

리더십 팀

이름	위치	테뉴어	보상	소유권
Russell Shaw	CFO, Secretary & Director	2.3yrs	UK£158.08k	데이터 없음
James Cheek	CEO & Director	less than a year	데이터 없음	데이터 없음
Gino Miele	Chief Scientific Officer & Executive Director	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: GDR 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Russell Shaw	CFO, Secretary & Director	no data	UK£158.08k	데이터 없음
James Cheek	CEO & Director	less than a year	데이터 없음	데이터 없음
Gino Miele	Chief Scientific Officer & Executive Director	less than a year	데이터 없음	데이터 없음
Ian Gilham	Independent Non-Executive Chairman	9.7yrs	UK£65.00k	0.11% £ 24.1k
Chris Henry Yates	Independent Non-Executive Director	5.9yrs	UK£35.00k	0.012% £ 2.7k
Thomas Lindsay	Independent Non-Executive Director	6.3yrs	UK£35.00k	0.048% £ 10.3k

5.9yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 이사회: GDR 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.

genedrive 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

genedrive plc, Annual General Meeting, Dec 29, 2023

genedrive plc Announces Chief Executive Officer Changes

genedrive plc, Annual General Meeting, Dec 29, 2022

High number of new directors

High number of new directors

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Recent updates

Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug Administration

genedrive plc has completed a Follow-on Equity Offering in the amount of £6 million.

New major risk - Shareholder dilution

genedrive plc has filed a Follow-on Equity Offering in the amount of £3.5 million.

New major risk - Shareholder dilution

genedrive plc to Report First Half, 2024 Results on Mar 28, 2024

New major risk - Market cap size

genedrive plc, Annual General Meeting, Dec 29, 2023

New major risk - Share price stability

Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022)

New major risk - Market cap size

genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023

New minor risk - Financial data availability

genedrive plc Announces Chief Executive Officer Changes

Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 System

Is genedrive (LON:GDR) In A Good Position To Invest In Growth?

genedrive plc, Annual General Meeting, Dec 29, 2022

Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021)

genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022

genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product Range

Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel Treatment

Here's Why We're Watching genedrive's (LON:GDR) Cash Burn Situation

NICE to Evaluate the Genedrive MT-RNR1 Test

High number of new directors

Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory Agency

High number of new directors

Now 25% undervalued after recent price drop

First half 2022 earnings released

Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Genedrive plc Provides Update on Point of Care Covid Test

genedrive plc to Report First Half, 2022 Results on Mar 29, 2022

genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kit

Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020)

Insufficient new directors

We're A Little Worried About genedrive's (LON:GDR) Cash Burn Rate

Genedrive COVID-19 Point of Care device update

Here's Why genedrive (LON:GDR) Must Use Its Cash Wisely

First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020)

New 90-day high: UK£1.49

genedrive plc Enters Distribution Agreement with Mountain Horse Solutions

genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss Assay

New 90-day high: UK£0.98

genedrive plc Enters into Distribution Agreement with Beckman Coulter Life Sciences

Is genedrive's (LON:GDR) Share Price Gain Of 252% Well Earned?

genedrive plc to Report First Half, 2021 Results on Mar 25, 2021

New 90-day low: UK£0.42

genedrive plc, Annual General Meeting, Dec 30, 2020

New 90-day low: UK£0.49

Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation Study

Full year 2020 earnings released: UK£0.55 loss per share

Earnings beat expectations, revenue disappoints

Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India Study

Full year 2020 earnings released: UK£0.55 loss per share

Earnings beat expectations, revenue disappoints

New 90-day low: UK£0.68

genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020

genedrive plc Announces South African Approval

genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNA

New 90-day high: UK£1.34

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령